MedTrace Logo

Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer

NCT02975141 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-08-13

No results posted yet for this study

Summary

This study sets out to determine the maximum tolerated dose (MTD) of afatinib in combination with gemcitabine/nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. The identified MTD will serve as recommended phase II dose (RP2D).

Conditions

Interventions

DRUG

Afatinib 30Mg Tab

Study Drug

DRUG

Afatinib 40Mg Tab

Study Drug

DRUG

Gemzar

Chemotherapy Backbone

DRUG

Abraxane

Chemotherapy Backbone

Sponsors & Collaborators

  • Technical University of Munich

    collaborator OTHER

  • University of Cologne

    collaborator OTHER

  • PD Dr. med. Volker Heinemann

    lead OTHER

Principal Investigators

  • Volker Heinemann, Professor · University of Munich - Klinikum Großhadern

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2018-12-31
Completion
2019-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02975141 on ClinicalTrials.gov